Nycomed to build API plant in Russia

Swiss drug maker Nycomed is planning an $84-million manufacturing plant in Russia, making it one of the first foreign manufacturers of active pharmaceutical ingredients.

The drugmaker will choose a greenfield site this quarter after two years of study, says Russia Profile.  It will be one of few foreign pharmaceutical companies in Russia, joining French concern Servier, which opened a $56-million plant in Moscow in 2007.

Russia Profile notes that most of Russia's 600 pharma plants are Soviet vintage. "It is a widely held belief that if the government enforces GMP upgrades, then the share of local manufacturers in the pharmaceutical industry will significantly drop--a result diametrically opposed to the government's declared strategy of increasing the share of local manufacturers from some 20 percent in 2008 to 50 percent by 2020," according to the publication.

- here's the Russia Profile article


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.